TNFA
Income statement / Annual
Last year (2023), TNF Pharmaceuticals, Inc.'s total revenue was $0.00,
and the percentage change from the previous year is not available.
In 2023, TNF Pharmaceuticals, Inc.'s net income was -$4.00 M.
See TNF Pharmaceuticals, Inc.’s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
| Period Ended |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
| Operating Revenue |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$1.67 M
|
$3.35 M
|
$2.96 M
|
| Cost of Revenue |
$0.00 |
$0.00 |
$0.00 |
$29,452.00 |
$74,064.00 |
$1.71 M |
$2.58 M |
$1.25 M |
| Gross Profit |
$0.00 |
$0.00 |
$0.00 |
-$29,452.00 |
-$74,064.00 |
-$43,823.00 |
$777,472.00 |
$1.71 M |
| Gross Profit Ratio |
0 |
0 |
0 |
0 |
0 |
-0.03 |
0.23 |
0.58 |
| Research and Development
Expenses |
$7.87 M
|
$9.07 M
|
$6.75 M
|
$7.96 M
|
$3.63 M
|
$1.06 M
|
$1.26 M
|
$1.19 M
|
| General & Administrative
Expenses |
$5.44 M
|
$6.22 M
|
$21.46 M
|
$5.81 M
|
$5.76 M
|
$0.00
|
$0.00
|
$0.00
|
| Selling & Marketing
Expenses |
$3.05 M
|
$0.00
|
$0.00
|
-$1.52 M
|
-$2.44 M
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General &
Administrative Expenses |
$8.49 M
|
$6.22 M
|
$21.46 M
|
$4.29 M
|
$3.32 M
|
$7.45 M
|
$6.13 M
|
$3.85 M
|
| Other Expenses |
$762,834.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Operating Expenses |
$16.36 M |
$15.28 M |
$28.20 M |
$12.26 M |
$3.32 M |
$8.51 M |
$7.39 M |
$5.04 M |
| Cost And Expenses |
$17.12 M |
$15.28 M |
$28.20 M |
$12.29 M |
$3.40 M |
$10.22 M |
$9.97 M |
$6.29 M |
| Interest Income |
$455,570.00 |
$83,991.00 |
$8,907.00 |
$141.00 |
$101,483.00 |
$165,840.00 |
$7,378.00 |
$21,784.00 |
| Interest Expense |
$0.00 |
$0.00 |
$608,460.00 |
$1.19 M |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Depreciation &
Amortization |
$13.12 M
|
$15.28 M
|
$18,334.00
|
$29,452.00
|
$74,064.00
|
$234,486.00
|
$249,894.00
|
$286,162.00
|
| EBITDA |
-$4.00 M
|
$0.00
|
-$29.28 M
|
-$12.12 M
|
-$3.31 M
|
-$10.61 M
|
-$7.12 M
|
-$3.02 M
|
| EBITDA Ratio |
0 |
0 |
0 |
0 |
0 |
-5 |
-1.9 |
-1.03 |
| Operating Income Ratio
|
0
|
0
|
0
|
0
|
0
|
-5.14
|
-1.97
|
-1.12
|
| Total Other
Income/Expenses Net |
$13.12 M
|
$85,427.00
|
-$1.08 M
|
$141.00
|
$15,808.00
|
-$2.29 M
|
-$752,520.00
|
$25,102.00
|
| Income Before Tax |
-$4.00 M |
-$15.20 M |
-$29.89 M |
-$12.15 M |
-$3.38 M |
-$10.85 M |
-$7.37 M |
-$3.30 M |
| Income Before Tax Ratio
|
0
|
0
|
0
|
0
|
0
|
-6.51
|
-2.2
|
-1.12
|
| Income Tax Expense |
$0.00 |
-$15.28 M |
-$18,334.00 |
$5.43 M |
$506,950.00 |
$5.00 |
-$4.00 |
-$2.00 |
| Net Income |
-$4.00 M |
-$15.20 M |
-$29.89 M |
-$17.58 M |
-$3.89 M |
-$10.85 M |
-$7.37 M |
-$3.30 M |
| Net Income Ratio |
0 |
0 |
0 |
0 |
0 |
-6.51 |
-2.2 |
-1.12 |
| EPS |
-5.33 |
-11.74 |
-25.61 |
-149.57 |
-380.79 |
-1423.62 |
-8937.35 |
-7008.35 |
| EPS Diluted |
-5.33 |
-11.74 |
-25.61 |
-149.57 |
-380.79 |
-1423.62 |
-8937.35 |
-7008.35 |
| Weighted Average Shares
Out |
$1.54 M
|
$1.29 M
|
$1.17 M
|
$117,544.00
|
$10,211.00
|
$7,620.72
|
$824.22
|
$471.37
|
| Weighted Average Shares
Out Diluted |
$1.54 M
|
$1.29 M
|
$1.17 M
|
$117,544.00
|
$10,211.00
|
$7,620.72
|
$824.22
|
$471.37
|
| Link |
|
|
|
|
|
|
|
|
